Xuewen Yu1, Pengxun Han2, Jiachuan Wang1, Huili Sun2, Mumin Shao1. 1. Department of Pathology, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine China. 2. Department of Nephrology, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine China.
Abstract
OBJECTIVES: To explore the expression and pathologic significance of renalase in tumor tissues of different molecular subtypes of breast cancer. DESIGN: Immunofluorescence methods and laser confocal scanning microscope observations were used to detect expression of renalase, estrogen receptor (ER), phospho-extracellular signal-regulated kinase 1 and 2 (p-ERK1/2), and phospho-signal transducer and activator of transcription (p-STAT3) in 58 cases of breast cancer tissue, 11 normal tissues, and 14 benign fibroadenomas. Statistical analysis of its expression in different molecular subtypes of breast cancer was employed. RESULTS: Compared with control tissue (benign lesions and normal breast tissue), renalase was highly expressed in invasive breast cancer and the difference was significant (P<0.0001). Renalase was also expressed significantly higher in ER-positive breast cancer, compared with control tissue (P<0.0001). There was a positive correlation between renalase and ER expression in breast cancer tissues (R=0.7246, P<0.0001) and a positive correlation between renalase and p-ERK 1/2 expression (R=0.6599, P<0.0001). Renalase had no significant correlation with p-STAT3 protein expression. CONCLUSION: Renalase is a new molecular marker for ER-positive breast cancer and may become a potential therapeutic target for the ER-positive/HER2-negative subtype breast cancer. Renalase may promote high ER expression and breast cancer cell proliferation and growth through the p-ERK1/2 pathway. IJCEP
OBJECTIVES: To explore the expression and pathologic significance of renalase in tumor tissues of different molecular subtypes of breast cancer. DESIGN: Immunofluorescence methods and laser confocal scanning microscope observations were used to detect expression of renalase, estrogen receptor (ER), phospho-extracellular signal-regulated kinase 1 and 2 (p-ERK1/2), and phospho-signal transducer and activator of transcription (p-STAT3) in 58 cases of breast cancer tissue, 11 normal tissues, and 14 benign fibroadenomas. Statistical analysis of its expression in different molecular subtypes of breast cancer was employed. RESULTS: Compared with control tissue (benign lesions and normal breast tissue), renalase was highly expressed in invasive breast cancer and the difference was significant (P<0.0001). Renalase was also expressed significantly higher in ER-positive breast cancer, compared with control tissue (P<0.0001). There was a positive correlation between renalase and ER expression in breast cancer tissues (R=0.7246, P<0.0001) and a positive correlation between renalase and p-ERK 1/2 expression (R=0.6599, P<0.0001). Renalase had no significant correlation with p-STAT3 protein expression. CONCLUSION:Renalase is a new molecular marker for ER-positive breast cancer and may become a potential therapeutic target for the ER-positive/HER2-negative subtype breast cancer. Renalase may promote high ER expression and breast cancer cell proliferation and growth through the p-ERK1/2 pathway. IJCEP